Tritonix.ai

News / Korea / yonhap_finance

KOSPI Surges Over 2% in Early Trading, Eyeing 7,000 Milestone

yonhap_finance · 2026-08-27

The KOSPI index jumped more than 2% in early trading on the 27th, reclaiming the 6,900 level and pushing toward the 7,000 mark.

What Happened

Market Movement: The KOSPI index opened with a strong rally on the 27th, climbing over 2% in early session trading. As of 9:01 AM, the index stood at 6,976.38, up 168.17 points or 2.47% from the previous close.

Index Performance: The index started the day at 6,996.12, marking a significant 2.76% gain from the prior session. It is currently making a concerted effort to break through the 7,000-point threshold.

KOSDAQ Status: The KOSDAQ index is also showing positive momentum, rising 6.15 points or 0.74% to reach 833.02 at the same time. This broad market rally suggests an improvement in overall investor sentiment.

Outlook: Strong buying pressure early in the session is driving the current gains. Investors are now closely watching whether the index can successfully consolidate above the 7,000 level to maintain this upward trend.

Read original

Latest in Korea

Hana Securities Urges SK Innovation to Strengthen Shareholder Returns Post-Merger

Energy Minerals · yonhap_finance · 2026-08-26

Hana Securities analyzes SK Innovation's merger with SKIET as a defensive move to mitigate financial risks, while calling for clearer shareholder return policies.

096770

Analysts Divided Over Hyundai Motor's Stance on Shareholder Returns

Consumer Durables · yonhap_finance · 2026-08-26

Hyundai Motor's decision to maintain its current shareholder return policy has sparked debate among analysts regarding the need for a shift in strategy.

005380

Nvidia's Earnings Beat Sparks Optimism for Semiconductor Sector Recovery

Electronic Technology · yonhap_finance · 2026-08-26

Nvidia's strong quarterly performance has boosted investor sentiment for semiconductor stocks, with experts anticipating a rebound for major memory chipmakers.

Daol Investment Securities Raises SK Biopharmaceuticals Price Target on New Drug Acquisition

Health Technology · yonhap_finance · 2026-08-26

Daol Investment Securities has upgraded its price target for SK Biopharmaceuticals to 160,000 KRW, citing the strategic addition of the epilepsy drug Opakalim.

326030